20240804-德邦证券-和记黄埔-00013.HK-呋喹替尼美国销售超预期_产品催化密集_7页_1mb

Summary

Hutchinson Pharmaceuticals reported strong financial and operational results for its 2024 mid-year fiscal period, with the company maintaining an "Add" rating and target price unchanged. The 2024 full-year revenue guidance for oncology/immunology is between $300–$400 million, with a significant portion driven by Furqinib (fruqaclidinium) and other key oncology products.
The company's pipeline is advancing well, with multiple regulatory filings and approvals in the US, Japan, and other markets for products like Savolitinib (c-MET inhibitor) and Xanatashe (EZH2 inhibitor). Several new drug applications (NDAs) and global studies are active and expected to yield positive outcomes. The company’s market position continues to strengthen through international expansion and drug development progress.

Introduction

This report provides an overview of Hutchison’s business performance, key product developments, pipeline updates, financial outlook, and investment risks.

Event Summary

2024 Mid-Year Financial Highlights

• Revenue: US$1.687 billion in the first half of 2024, with oncology product revenue growing 59% (equivalent to +64% at constant exchange rates).
• Costs: R&D expenses decreased 34% YoY to approximately US$95.3 million; SG&A expenses were US$57.8 million.
• Net Profit: US$25.8 million in the first half of 2024, with cash reserves at approximately US$800 million.

Revenue Breakdown

• Furqinib (for "Fruzia"): US$1.3 billion in 2024H1 sales in the US, continuing strong growth momentum.
• Other Key Products:
  • Selipradin (SYK inhibitor): Sales increased 12% YoY to US$25.4 million.
  • Savolitinib (c-MET inhibitor): Sales grew 18% YoY to US$25.9 million.
• Upfront Payments and Milestones: US$33.8 million from Wockhardt for upfront fees, milestones, and research service revenues.

Product & Clinical Development Progress

Furqinib (“Fruzia”)

• Since authorization to Takeda in 2023, Furqinib has expanded into Japan, Europe, and other regions.
• Already approved in the US (2023) and EU (June 2024).
• Domestic tumors such as gastric, cervical, and renal cell carcinoma are under evaluation.

Savolitinib (c-MET Inhibitor)

• 7 registration studies, including 3 global trials.
• Ongoing Phase III trial in MET mutation-positive NSCLC (SACHI study); potentially eligible for NDA submission in 2024.

Xanatashe (EZH2 Inhibitor)

• Approved in Hong Kong for relapsed/refractory follicular lymphoma in 2024.
• NDA submission pending with Chinese NMPA

Upcoming Key Milestones

• October 2024: Expected top-line results from Phase II/III trial of Furqinib in second-line gastric cancer.
• End of 2024: FDA submission expected for Savolitinib's NDA based on FASTER study progression.
• Various regulatory submissions ongoing globally, positioning the company for significant near-term growth.

Investment Thesis & Financial Projections

• Maintain a strong view on Hutchison as a growth catalyst in the oncology space.
• Projected Revenue (2024E–2026E):
  • Full-year oncology revenue estimated at US$636 million, rising to US$997 million by 2026.
• Projected Net Profit: US$-105.8 million (2024E), turning profitable by 2026 with projected net profit of US$1.7 billion.
• Valuation Metrics (2024–2026):
  • P/E ratios: 31–32x
  • P/B ratios: 4.5–4.4x
• Valuation Range: Currently trading at $34.7 HKD per share, with sustained strong performance expected by 2026.

Risks

• Clinical trial failure possibility via accelerated pipeline progression.
• Market competition intensification from established players.
• Product sales falling short of projections.

Key Financial Ratios (2024E–2026E)

Legal Notice

This document contains the analysts' views as of 31 July 2024. The information contained herein is subject to securities regulations. No contractual obligations have been assumed to make updates or revisions.